Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01142908 · ClinicalTrials.gov registry record · NA

Cardiovascular Intervention Improvement Telemedicine Study

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
428
Enrollment target

NCT01142908: Completed NA study, sponsored by VA Office of Research and Development.

NCT01142908 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 428 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01142908, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
428 participants
Enrollment target

Study Summary

Cardiovascular disease (CVD) is the leading cause of death in the United States; more than 80% of veterans have \> 2 risk factors for CVD. Our study is one of the first to examine the implementation of a tailored behavioral/educational self-management intervention in primary care clinics designed to improve CVD risk. The proposed study could result in a leap forward in CVD risk management among veterans for several reasons: 1) ) This is a novel extension of our previous interventions that have demonstrated improved BP, now designed to address multiple chronic conditions contributing to CVD risk, particularly hyperlipidemia and diabetes. The study focuses on both multiple CVD-related risk factor management and medication management 2) The intervention is multi-behavioral; it addresses patients' various health behavior (e.g., smoking, diet, and medication adherence). 3) Components of the intervention will include specific recommendations and transportability of intervention application software and tracking packages that will allow clinic managers to implement the intervention if it is effective.

Primary Outcome

Components of the Framingham include gender, age fixed at baseline, systolic blood pressure (presence/absence of blood pressure medications at each time point \[combination of administrative med data pull and self-report at assessment\]), total cholesterol, HDL cholesterol, smoking status (assessed via self-report at each study survey), and diabetes (diabetes is a combination of self-report and VA Computerized Patient Record System (CPRS) data review). "New cases" of diabetes are allowed to be u

Interventions

  • BEHAVIORAL Pharmacist CVD

Trial Details

FieldValue
Enrollment Target 428 participants
Start Date 2011-11-01
Est. Completion 2015-05-22
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT01142908 record still lists

NCT01142908 is an interventional study that assigns participants to a tested intervention. The registered 428 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (70% lower).

The record links to 0 conditions, and to 1 intervention - of which Pharmacist CVD is the first listed.

NCT01142908 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01142908 about?

NCT01142908 is a clinical study titled "Cardiovascular Intervention Improvement Telemedicine Study". Cardiovascular disease (CVD) is the leading cause of death in the United States; more than 80% of veterans have \> 2 risk factors for CVD. Our study is one of the first to examine the implementation of a tailored behavioral/educational self-management intervention in primary care clinics designed to...

What is the current status of trial NCT01142908?

This trial is currently completed. It is a NA study. The enrollment target is 428 participants. The study started on 2011-11-01. Estimated completion is 2015-05-22.

What interventions are being tested in trial NCT01142908?

The interventions under investigation include: Pharmacist CVD (BEHAVIORAL).

Who is sponsoring clinical trial NCT01142908?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01142908's enrollment target sits among peer trials

428 236th of 2000 higher than 1,765 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05566431 · 428 participants · NA

    Benchmark Evidence Led by Latin America: Trial of Intracranial Pressure - Pediatrics

  • NCT05646316 · 428 participants · Phase 3

    Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer

  • NCT05797610 · 428 participants · Phase 3

    A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

  • NCT06073626 · 428 participants · NA

    Addressing Genomic Disparities in Cancer Survivors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01142908, the US trial registry maintained by the National Library of Medicine. NCT01142908 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.